Table 2.
Incidence of eGFR<60 ml/min per 1.73 m2 and eGFR decline ≥30% according to nonsteroidal anti-inflammatory drug use
| NSAID Use | Subject | eGFR<60 ml/min per 1.73 m2 | eGFR Decline ≥30% | Composite a | |||
|---|---|---|---|---|---|---|---|
| Event | Incidence Rate b | Event | Incidence Rate b | Event | Incidence Rate b | ||
| No NSAIDs | 1,734,701 | 263,112 | 22.8 (22.7 to 22.9) | 373,051 | 33.4 (33.3 to 33.6) | 402,932 | 36.8 (36.6 to 36.9) |
| Any NSAIDs | 154,991 | 8736 | 33.0 (32.3 to 33.8) | 15,335 | 62.1 (61.0 to 63.2) | 16,574 | 68.0 (66.9 to 69.1) |
| Celecoxib | 1274 | 213 | 32.2 (27.1 to 38.5) | 375 | 63.8 (56.4 to 72.4) | 392 | 67.8 (60.2 to 76.7) |
| Etoricoxib | 1030 | 183 | 45.0 (38.7 to 52.6) | 322 | 88.8 (79.0 to 100.0) | 335 | 93.5 (83.6 to 104.8) |
| Diclofenac | 90,829 | 5925 | 34.1 (33.2 to 35.0) | 10,487 | 64.7 (63.4 to 66.0) | 11,267 | 70.4 (69.0 to 71.8) |
| Ibuprofen | 15,169 | 465 | 24.8 (22.5 to 27.5) | 817 | 45.9 (42.6 to 49.5) | 930 | 52.9 (49.4 to 56.7) |
| Indomethacin | 5199 | 320 | 33.5 (30.0 to 37.6) | 505 | 56.5 (51.5 to 62.2) | 577 | 65.8 (60.3 to 71.9) |
| Mefenamic acid | 10,697 | 144 | 16.7 (11.8 to 24.4) | 284 | 34.0 (27.4 to 42.6) | 306 | 37.0 (30.1 to 46.1) |
| Naproxen | 28,966 | 1361 | 34.5 (32.6 to 36.5) | 2343 | 63.5 (60.8 to 66.3) | 2541 | 69.7 (66.9 to 72.7) |
| Piroxicam | 1308 | 78 | 33.4 (25.3 to 45.1) | 124 | 56.7 (44.7 to 72.8) | 138 | 63.9 (50.6 to 81.9) |
| Sulindac | 519 | 47 | 35.8 (27.3 to 47.9) | 78 | 63.7 (50.1 to 82.2) | 90 | 76.4 (61.1 to 96.7) |
NSAID, nonsteroidal anti-inflammatory drug.
a
Composite is defined by either incident eGFR <60 ml/min per 1.73 m2 or eGFR decline ≥30%.
b
Incidence rates (cases per 1000 person-year) with 95% confidence intervals are on the basis of Poisson distribution.